30 related articles for article (PubMed ID: 38725213)
1. The other side of the coin in renal replacement therapies: the burden on caregivers.
Bardak S; Demir S; Aslan E; Turgutalp K; Celikcan HD; Dolarslan ME; Kılıcarslan C; Karasu F; Gunes AJ; Kurt C; Kıykım A
Int Urol Nephrol; 2019 Feb; 51(2):343-349. PubMed ID: 30515731
[TBL] [Abstract][Full Text] [Related]
2. Direct medical costs of end-stage kidney disease and renal replacement therapy: a cohort study in Guangzhou City, southern China.
Zhang H; Zhang C; Zhu S; Ye H; Zhang D
BMC Health Serv Res; 2020 Feb; 20(1):122. PubMed ID: 32059726
[TBL] [Abstract][Full Text] [Related]
3. Direct and indirect costs of end-stage renal disease patients in the first and second years after initiation of nocturnal home haemodialysis, hospital haemodialysis and peritoneal dialysis.
Wong CKH; Chen J; Fung SKS; Mok MMY; Cheng YL; Kong I; Lo WK; Lui SL; Chan TM; Lam CLK
Nephrol Dial Transplant; 2019 Sep; 34(9):1565-1576. PubMed ID: 30668781
[TBL] [Abstract][Full Text] [Related]
4. A cost evaluation of peritoneal dialysis and hemodialysis in the treatment of end-stage renal disease in Sao Paulo, Brazil.
de Abreu MM; Walker DR; Sesso RC; Ferraz MB
Perit Dial Int; 2013; 33(3):304-15. PubMed ID: 23209041
[TBL] [Abstract][Full Text] [Related]
5. Economic burden and cost-utility analysis of three renal replacement therapies in ESRD patients from Yunnan Province, China.
Wu H; Li Q; Cai Y; Zhang J; Cui W; Zhou Z
Int Urol Nephrol; 2020 Mar; 52(3):573-579. PubMed ID: 32009220
[TBL] [Abstract][Full Text] [Related]
6. Economic Burden of Patients with End-Stage Kidney Disease and Their Caregivers: A Scoping Review.
Shafik N; Ibrahim N; Gafor AHA
Saudi J Kidney Dis Transpl; 2023 Nov; 34(6):642-654. PubMed ID: 38725213
[TBL] [Abstract][Full Text] [Related]
7. Healthcare systems and end-stage renal disease (ESRD) therapies--an international review: costs and reimbursement/funding of ESRD therapies.
De Vecchi AF; Dratwa M; Wiedemann ME
Nephrol Dial Transplant; 1999; 14 Suppl 6():31-41. PubMed ID: 10528710
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of dialysis therapies.
Klarenbach S; Manns B
Semin Nephrol; 2009 Sep; 29(5):524-32. PubMed ID: 19751898
[TBL] [Abstract][Full Text] [Related]
9. The direct and indirect financial costs of informal cancer care: A scoping review.
Coumoundouros C; Ould Brahim L; Lambert SD; McCusker J
Health Soc Care Community; 2019 Sep; 27(5):e622-e636. PubMed ID: 31293013
[TBL] [Abstract][Full Text] [Related]
10. Health-care economics and peritoneal dialysis.
Nissenson AR
Perit Dial Int; 1996; 16 Suppl 1():S373-7. PubMed ID: 8728226
[TBL] [Abstract][Full Text] [Related]
11. Peritoneal dialysis: an underutilized modality.
Jiwakanon S; Chiu YW; Kalantar-Zadeh K; Mehrotra R
Curr Opin Nephrol Hypertens; 2010 Nov; 19(6):573-7. PubMed ID: 20639759
[TBL] [Abstract][Full Text] [Related]
12. Cost Barriers to More Widespread Use of Peritoneal Dialysis in the United States.
Baerman EA; Kaplan J; Shen JI; Winkelmayer WC; Erickson KF
J Am Soc Nephrol; 2022 Jun; 33(6):1063-1072. PubMed ID: 35314456
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
